BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1468 related articles for article (PubMed ID: 20137358)

  • 1. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of clinicopathology and prognosis in 181 patients with gastrointestinal stromal tumors].
    Zhang Y; Cao H; Wang M; Shen DP; Shen ZY; Ni XZ; Wu ZY; Shen YY; Liu Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):150-4. PubMed ID: 19296250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
    Hassan I; You YN; Shyyan R; Dozois EJ; Smyrk TC; Okuno SH; Schleck CD; Hodge DO; Donohue JH
    Ann Surg Oncol; 2008 Jan; 15(1):52-9. PubMed ID: 18000711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
    Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
    An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S
    Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
    Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
    BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An audit of surgical management of gastrointestinal stromal tumours (GIST).
    Bucher P; Egger JF; Gervaz P; Ris F; Weintraub D; Villiger P; Buhler LH; Morel P
    Eur J Surg Oncol; 2006 Apr; 32(3):310-4. PubMed ID: 16414236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
    Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
    Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.
    Chen CW; Wu CC; Hsiao CW; Fang FC; Lee TY; Che FC; Tsai WC; Jao SW
    Z Gastroenterol; 2008 Aug; 46(8):760-5. PubMed ID: 18759198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of gastrointestinal stromal tumors].
    Zhang W; Ye ZY; Shao QS; Zhao ZS; Wang YD; Xu XD
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul; 12(4):378-81. PubMed ID: 19598024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of prognostic factors for patients with gastrointestinal stromal tumors].
    Jie ZG; Xie XP; Qin KW; Liu Y; Li ZR; Dai AB; Yao YX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2005 May; 8(3):210-2. PubMed ID: 16167229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
    Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
    Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
    Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases.
    Otani Y; Furukawa T; Yoshida M; Saikawa Y; Wada N; Ueda M; Kubota T; Mukai M; Kameyama K; Sugino Y; Kumai K; Kitajima M
    Surgery; 2006 Apr; 139(4):484-92. PubMed ID: 16627057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH; Wang PZ; Shao YF; Wu XT; Gu J; Li R; Wan DS; Ding KF; Shi YQ; Yu JR; Lu HS; Zou XM; Bi JW; Sun YH; Lu YF; Chen DD; Zhang XH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients.
    Song Z; Wang JL; Pan YL; Tao DY; Gan MF; Huang KE
    Hepatogastroenterology; 2009; 56(89):149-53. PubMed ID: 19453047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.